Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature

Fabienne G. M. Smeets; Paulien R. Liedorp; Marjolein van der Poel; Razvan L. Miclea; Ad A. M. Masclee; Marieke Pierik

doi:10.1093/ecco-jcc/jjz084

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature

Fabienne G. M. Smeets^*
, Paulien R. Liedorp
, Marjolein van der Poel
, Razvan L. Miclea
, Ad A. M. Masclee
, Marieke Pierik

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.

Original language	English
Pages (from-to)	1470-1473
Number of pages	4
Journal	Journal of Crohn's & Colitis
Volume	13
Issue number	11
DOIs	https://doi.org/10.1093/ecco-jcc/jjz084
Publication status	Published - Nov 2019

Keywords

Ustekinumab
lymphoma
Crohn's disease
INFLAMMATORY-BOWEL-DISEASE
MAINTENANCE THERAPY
TERM SAFETY
CANCER-RISK
INDUCTION

Access to Document

10.1093/ecco-jcc/jjz084Licence: CC BY-NC

Fingerprint

Dive into the research topics of 'Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature'. Together they form a unique fingerprint.

Cite this

Smeets, F. G. M., Liedorp, P. R., van der Poel, M., Miclea, R. L., Masclee, A. A. M., & Pierik, M. (2019). Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. Journal of Crohn's & Colitis, 13(11), 1470-1473. https://doi.org/10.1093/ecco-jcc/jjz084

Smeets, Fabienne G. M. ; Liedorp, Paulien R. ; van der Poel, Marjolein et al. / Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment : A Case Report and Review of the Literature. In: Journal of Crohn's & Colitis. 2019 ; Vol. 13, No. 11. pp. 1470-1473.

@article{9b8bda8f63ac4e38b5b4f406b467ce6e,

title = "Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature",

abstract = "Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.",

keywords = "Ustekinumab, lymphoma, Crohn's disease, INFLAMMATORY-BOWEL-DISEASE, MAINTENANCE THERAPY, TERM SAFETY, CANCER-RISK, INDUCTION",

author = "Smeets, \{Fabienne G. M.\} and Liedorp, \{Paulien R.\} and \{van der Poel\}, Marjolein and Miclea, \{Razvan L.\} and Masclee, \{Ad A. M.\} and Marieke Pierik",

note = "Publisher Copyright: Copyright {\textcopyright} 2019 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].",

year = "2019",

month = nov,

doi = "10.1093/ecco-jcc/jjz084",

language = "English",

volume = "13",

pages = "1470--1473",

journal = "Journal of Crohn's \& Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "11",

}

Smeets, FGM, Liedorp, PR, van der Poel, M , Miclea, RL, Masclee, AAM & Pierik, M 2019, 'Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature', Journal of Crohn's & Colitis, vol. 13, no. 11, pp. 1470-1473. https://doi.org/10.1093/ecco-jcc/jjz084

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. / Smeets, Fabienne G. M.; Liedorp, Paulien R.; van der Poel, Marjolein et al.
In: Journal of Crohn's & Colitis, Vol. 13, No. 11, 11.2019, p. 1470-1473.

Research output: Contribution to journal › (Systematic) Review article › peer-review

TY - JOUR

T1 - Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment

T2 - A Case Report and Review of the Literature

AU - Smeets, Fabienne G. M.

AU - Liedorp, Paulien R.

AU - van der Poel, Marjolein

AU - Miclea, Razvan L.

AU - Masclee, Ad A. M.

AU - Pierik, Marieke

N1 - Publisher Copyright: Copyright © 2019 European Crohn's and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

PY - 2019/11

Y1 - 2019/11

N2 - Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.

AB - Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.

KW - Ustekinumab

KW - lymphoma

KW - Crohn's disease

KW - INFLAMMATORY-BOWEL-DISEASE

KW - MAINTENANCE THERAPY

KW - TERM SAFETY

KW - CANCER-RISK

KW - INDUCTION

U2 - 10.1093/ecco-jcc/jjz084

DO - 10.1093/ecco-jcc/jjz084

M3 - (Systematic) Review article

C2 - 31116402

SN - 1873-9946

VL - 13

SP - 1470

EP - 1473

JO - Journal of Crohn's & Colitis

JF - Journal of Crohn's & Colitis

IS - 11

ER -

Smeets FGM, Liedorp PR, van der Poel M , Miclea RL, Masclee AAM, Pierik M. Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. Journal of Crohn's & Colitis. 2019 Nov;13(11):1470-1473. doi: 10.1093/ecco-jcc/jjz084